Reece E A, Gabrielli S, Cullen M T, Zheng X Z, Hobbins J C, Harris E N
Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, CT 06510-8063.
Am J Obstet Gynecol. 1990 Jul;163(1 Pt 1):162-9. doi: 10.1016/s0002-9378(11)90692-9.
Antiphospholipid antibodies, which include lupus-like anticoagulant and anticardiolipin antibody, have been linked to a number of adverse pregnancy outcomes, although their exact pathogenic mechanisms remain poorly defined. The relative risk of complications such as intrauterine growth retardation, spontaneous abortions, and stillbirth in patients with antiphospholipid antibodies also remains undetermined. Heightened attention has been focused on the association, leading to investigations into the pathogenesis. Uncontrolled studies have also explored therapeutic regimens such as aspirin, steroids, and heparin, and clinical trials have used various treatment protocols. Although knowledge into the association of antiphospholipid antibodies and recurrent adverse pregnancy outcome is limited and continues to evolve, this association provides new insights into the disease and offers promise for pharmacologic prophylaxis. In this article, current concepts on pathogenesis, diagnosis, and therapy are reviewed and recommendations are made for clinical care of these patients.
抗磷脂抗体，包括狼疮抗凝物和抗心磷脂抗体，与多种不良妊娠结局有关，尽管其确切的致病机制仍不清楚。抗磷脂抗体患者发生如胎儿生长受限、自然流产和死产等并发症的相对风险也尚未确定。人们对这种关联给予了更多关注，从而对发病机制展开了研究。非对照研究也探索了阿司匹林、类固醇和肝素等治疗方案，临床试验采用了各种治疗方案。尽管关于抗磷脂抗体与复发性不良妊娠结局之间关联的认识有限且仍在不断发展，但这种关联为该疾病提供了新的见解，并为药物预防带来了希望。在本文中，我们回顾了当前关于发病机制、诊断和治疗的概念，并对这些患者的临床护理提出了建议。
